Back to 2011 Program

Background: More than 250,000 patients are diagnosed with liver metastases every year in USA. Less than 20% of those lesions are amenable to definitive surgical management due to advance local disease or a medical condition. Non-surgical therapies, i.e. TACE, RFA have limited response and no significant impact on patient survival. SBRT has emerged as an alternative therapy. Objective: to determine the response of liver metastases to SBRT and if SBRT treatment may confer survival benefit to patients with non-resectable liver metastases. Methods: patients with secondary liver tumors treated with SBRT from four Academic Medical Centers were entered into a common database. Descriptive statistics and survival curves were performed using SPSS. Results: 155 patients underwent SBRT for liver metastases. 52% of tumors originated in the GI tract while 35% were from the thorax including breast. 89% of treated neoplasms responded to SBRT at a median dose of 32 Gy in 3 consecutive fractions (median). A Grade III/IV local response was observed with a mean decrease in maximum diameter from 4.3 ± 1.9 cm to 2.5 ± 1.3cm and a calculated mean total tumor volume reduction of 39%. Recurrences in the radiated field were observed in 2% of treated cases. SBRT did not conferred a survival advantage in patients with secondary liver tumors when compared with matched controls (p>0.05). Systemic recurrences were common. 42% of patients were readmitted to the hospital for medical complications. No complications attributable to fiducial placement or SBRT treatment were observed. Conclusion: SBRT is a safe and effective treatment modality for the local control of secondary liver neoplasms. Further analyses are undergoing to determine grade of response to SBRT according to tumor type.